IL287665A - Combined treatments including apremilaste and tyk2 inhibitors - Google Patents

Combined treatments including apremilaste and tyk2 inhibitors

Info

Publication number
IL287665A
IL287665A IL287665A IL28766521A IL287665A IL 287665 A IL287665 A IL 287665A IL 287665 A IL287665 A IL 287665A IL 28766521 A IL28766521 A IL 28766521A IL 287665 A IL287665 A IL 287665A
Authority
IL
Israel
Prior art keywords
day
substituted
per day
dioxo
methylsulfonyl
Prior art date
Application number
IL287665A
Other languages
English (en)
Hebrew (he)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of IL287665A publication Critical patent/IL287665A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL287665A 2019-04-30 2019-04-30 Combined treatments including apremilaste and tyk2 inhibitors IL287665A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (fr) 2019-04-30 2019-04-30 Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2

Publications (1)

Publication Number Publication Date
IL287665A true IL287665A (en) 2022-07-01

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
IL287665A IL287665A (en) 2019-04-30 2019-04-30 Combined treatments including apremilaste and tyk2 inhibitors
IL287670A IL287670A (en) 2019-04-30 2021-10-28 Combined treatments including apremilaste and tyk2 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL287670A IL287670A (en) 2019-04-30 2021-10-28 Combined treatments including apremilaste and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (fr)
JP (2) JP2022537877A (fr)
KR (2) KR20220002488A (fr)
CN (3) CN114269336A (fr)
AU (2) AU2019443366A1 (fr)
BR (2) BR112021021809A2 (fr)
CA (2) CA3138473A1 (fr)
CL (1) CL2021002847A1 (fr)
CO (2) CO2021015622A2 (fr)
IL (2) IL287665A (fr)
MA (1) MA55799A (fr)
MX (2) MX2021013317A (fr)
SG (2) SG11202112043PA (fr)
WO (2) WO2020222773A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269336A (zh) * 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法
JP2024508794A (ja) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
CA3207819A1 (fr) 2021-02-19 2022-08-25 Anjali Pandey Inhibiteurs de tyk2 et leurs utilisations
JP2024507253A (ja) 2021-02-19 2024-02-16 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
EP4335440A4 (fr) * 2021-05-04 2025-05-14 Shanghai Zheye Biotechnology Co., Ltd. Composé de pyridine hétérocyclique contenant de l'azote
CN118251222A (zh) * 2021-09-23 2024-06-25 百时美施贵宝公司 用tyk2抑制剂治疗脱发障碍的方法
EP4423086A1 (fr) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Agents de dégradation de tyk2 et leurs utilisations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
EP2638018A1 (fr) 2010-11-09 2013-09-18 Cellzome Limited Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2
ES2661583T3 (es) * 2011-04-28 2018-04-02 Celgene Corporation Métodos y composiciones usando inhibidores de PDE4 para el tratamiento y gestión de enfermedades autoinmunes e inflamatorias
HUE050327T2 (hu) 2011-12-27 2020-11-30 Amgen Europe Gmbh Készítmények (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metánszulfonil-etil]-4-acetilaminoizoindolin-1,3-dion tartalommal
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
EP2832734A4 (fr) 2012-03-28 2015-08-26 Takeda Pharmaceutical Composé hétérocyclique
US9296725B2 (en) 2012-05-24 2016-03-29 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
AU2013341186B2 (en) * 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CA2890935A1 (fr) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composes de pyrimidine a substitution d'amide alkyl utiles pour la modulation des il-12, il 23 et ifn.alpha
NZ628320A (en) * 2013-03-14 2017-04-28 Celgene Corp Treatment of psoriatic arthritis using apremilast
EP3029031A4 (fr) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Composé hétérocyclique
CN105793245B (zh) 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EP3080131B1 (fr) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Composés imidazopyridazines utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn-alpha
WO2015091584A1 (fr) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Composés de thiazolopyridine, compositions et leur utilisation comme inhibiteurs de la kinase tyk2
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
EP4019518A1 (fr) 2014-02-28 2022-06-29 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et utilisations associées
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
US10092541B2 (en) * 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
NO2721710T3 (fr) 2014-08-21 2018-03-31
WO2016047678A1 (fr) 2014-09-25 2016-03-31 武田薬品工業株式会社 Composé hétérocyclique
ES2930585T3 (es) 2015-02-27 2022-12-19 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
JP6802263B2 (ja) 2015-09-02 2020-12-16 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
ES2794779T3 (es) 2016-02-24 2020-11-19 Pfizer Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK
KR102531036B1 (ko) 2016-10-07 2023-05-09 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CN115448916B (zh) 2016-10-14 2026-04-28 武田药品工业株式会社 Tyk2抑制剂及其用途
JP7082120B2 (ja) 2016-10-21 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
KR102477063B1 (ko) 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
TWI868528B (zh) * 2017-03-08 2025-01-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑之生產方法
CN114269336A (zh) * 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法

Also Published As

Publication number Publication date
WO2020222773A1 (fr) 2020-11-05
AU2019443366A1 (en) 2021-12-02
JP2022537878A (ja) 2022-08-31
BR112021021826A8 (pt) 2022-06-21
KR20220002488A (ko) 2022-01-06
CN114206333A (zh) 2022-03-18
CA3138473A1 (fr) 2020-11-05
MX2021013317A (es) 2022-01-18
CN119454692A (zh) 2025-02-18
EP3962476A1 (fr) 2022-03-09
BR112021021826A2 (pt) 2022-01-04
SG11202112018YA (en) 2021-11-29
IL287670A (en) 2021-12-01
CO2021015614A2 (es) 2021-12-10
CL2021002847A1 (es) 2022-07-22
KR20220002489A (ko) 2022-01-06
CN114269336A (zh) 2022-04-01
BR112021021809A2 (pt) 2022-01-04
MX2021013318A (es) 2022-01-31
AU2020266143A1 (en) 2021-12-02
SG11202112043PA (en) 2021-11-29
EP3962475A1 (fr) 2022-03-09
WO2020223431A1 (fr) 2020-11-05
JP2022537877A (ja) 2022-08-31
JP7453251B2 (ja) 2024-03-19
MA55799A (fr) 2022-03-09
CA3138686A1 (fr) 2020-11-05
CO2021015622A2 (es) 2022-02-28

Similar Documents

Publication Publication Date Title
US20220339151A1 (en) Combination therapies comprising apremilast and tyk2 inhibitors
WO2020222773A1 (fr) Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
CN105311030A (zh) 用于抗肿瘤的螺取代化合物
JP2025510813A (ja) Ｔｙｋ２阻害剤及びその使用
WO2025157117A1 (fr) Utilisation de formes salines de composé et de formes cristallines de celui-ci dans le traitement d'une insuffisance cardiaque avec fraction d'éjection préservée
EP1256344A1 (fr) Remedes contre les maladies induites par l'endotheline
JP2025183397A (ja) 乾癬性関節炎の治療方法
JP2021008496A (ja) インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法
CN109310673A (zh) 用选择性cb2受体激动剂治疗的方法
JP2024170448A (ja) メイソインジゴの多形体およびメイソインジゴの改変された製剤
JP2005526022A5 (ja) 関節リウマチの処置
AU2010270425B2 (en) Use of benzydamine in the treatment of p40-dependent diseases
EA046759B1 (ru) Комбинированные терапии, содержащие апремиласт и ингибиторы tyk2
US20070082903A1 (en) Remedy for rheumatoid arthritis
TW202521113A (zh) 類風濕性關節炎治療藥
JPH08239322A (ja) ピロリジノン誘導体を含有する医薬組成物
WO2025002076A1 (fr) Utilisations d'un inhibiteur de mk2 dans la préparation de médicaments pour la prévention et/ou le traitement de maladies
CN121443296A (zh) 化合物1在治疗或预防肺纤维化或伴有纤维化的肺部疾病等疾病中的应用
WO2025113607A1 (fr) Médicaments pour une utilisation combinée dans le traitement d'une tumeur
TW200524612A (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors